ENSC - Company ID 0001716947
The table below shows Ensysce Biosciences, Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Revenue | $961.00K | $493.10K | $1.37M | $1.32M | $3.42M | $181.80K |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $3.35M | $2.95M | $1.92M | $1.89M | $1.69M | $947.23K |
Ensysce Biosciences, Inc. reported annual revenue of $5.07M for fiscal year 2025. That is down 2.8% from $5.21M in fiscal 2024. Over the 6 fiscal years shown, annual revenue grew from $3.93M (FY 2020) to $5.07M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $1.18M |
| $1.28M |
| $1.20M |
| $1.40M |
| $1.08M |
| $1.19M |
| Operating income | -$3.56M | -$3.74M | -$1.75M | -$1.97M | $644.75K | -$1.96M |
| Income tax | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - |
| EPS (diluted) | -$0.52 | -$1.29 | -$0.79 | -$1.39 | $1.00 | -$3.35 |